Martin Peter, Furman Richard R, Coleman Morton, Leonard John P
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, and New York Presbyterian Hospital, New York, New York 10021, USA.
Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5636s-5642s. doi: 10.1158/1078-0432.CCR-07-1085.
Led by the anti-CD20 antibody rituximab, therapeutic monoclonal antibodies have dramatically altered the treatment of patients with non-Hodgkin's lymphoma. As the understanding of the biology of this novel therapy improves, so does the potential for further progress. There are currently four monoclonal antibodies approved by the Food and Drug Administration for the treatment of B-cell malignancies and dozens more are in various stages of development. The indications for the currently available antibodies, both labeled and unlabeled, are being expanded to include first-line treatment, maintenance strategies, and combinations with chemotherapy. Newer agents are being engineered to target novel antigens, and to interact more specifically with the host immune system. These promising therapeutics face a significant challenge in evaluation and integration in the post-rituximab world.
在抗CD20抗体利妥昔单抗的引领下，治疗性单克隆抗体显著改变了非霍奇金淋巴瘤患者的治疗方式。随着对这种新型疗法生物学特性的理解不断深入，进一步取得进展的潜力也在增加。目前有四种单克隆抗体已获美国食品药品监督管理局批准用于治疗B细胞恶性肿瘤，还有数十种正处于不同的研发阶段。目前已获批及未获批的抗体的适应证正在扩大，包括一线治疗、维持治疗策略以及与化疗联合使用。新型药物正在被设计用于靶向新型抗原，并更特异性地与宿主免疫系统相互作用。在利妥昔单抗之后的时代，这些前景广阔的疗法在评估和整合方面面临重大挑战。
